BRI.TECH GMBH

Their core work

BRI.TECH GmbH is a Graz-based medtech SME focused on bioresorbable magnesium bone fixation implants — screws and similar devices designed to hold bone fragments together while they heal, then dissolve naturally in the body without requiring removal surgery. Their BriScrew project demonstrates they develop and validate these implants commercially, not just study them in a lab. They also contribute specialist implant knowledge to larger research networks, such as MgSafe, where their technology was investigated using advanced imaging techniques to monitor how magnesium degrades at the bone interface in living tissue. Their value lies in bridging product-level engineering with clinical safety evidence for a class of implants that is still gaining regulatory and market traction.

What they specialise in

How they've shifted over time

BRI.TECH entered H2020 through a commercially-oriented SME Phase 1 grant (BriScrew, 2017) focused on demonstrating the feasibility of their bioresorbable bone screw as a product — a classic early-stage medtech validation exercise with no published technical keywords beyond the device concept itself. By 2018 they had shifted toward scientific depth, joining MgSafe as a third-party contributor to an MSCA doctoral training network that studied imaging, degradation chemistry, and bone-interface behaviour in detail. This arc — from product feasibility toward evidence-based safety science — is typical of medtech SMEs that need clinical and regulatory backing to advance their device toward market.

BRI.TECH is building the scientific and safety evidence base around their magnesium implant technology, suggesting they are preparing for a regulatory or commercial push and would be a strong partner for consortia working on biodegradable orthopaedic devices, biomaterial safety, or implant monitoring technologies.

How they like to work

BRI.TECH has taken both a leadership role (coordinating their own SME Phase 1 project) and a specialist contributor role (third party in a large MSCA ITN network), which suggests flexibility in how they engage. The MgSafe consortium gave them access to 12 partners across 8 countries, a notably wide network for a company with only two projects — their technology was clearly valuable enough to attract inclusion in a major international training network. They appear to join large consortia when they bring a unique asset, not just capacity.

Despite only two projects, BRI.TECH has touched 12 distinct consortium partners across 8 European countries, driven largely by their third-party role in the multi-country MgSafe MSCA ITN. Their network is European in scope, centred on the academic and clinical research community working on biodegradable implants.

What sets them apart

BRI.TECH occupies a narrow but defensible niche: they are an actual manufacturer of magnesium-based bioresorbable bone screws who has also participated in advanced scientific research on how those implants behave in the body. Most academic groups study this material class without owning a product; most SME device makers lack the scientific network BRI.TECH has built through MgSafe. That combination — product ownership plus scientific credibility — makes them a compelling partner for clinical trials, regulatory dossier building, or applied research projects that need a real device to study.

Highlights from their portfolio

• BriScrew
  This was BRI.TECH's own coordinated project — an SME Phase 1 feasibility grant for their bioresorbable osteosynthesis screw, marking them as the originating company behind this technology.
• MgSafe
  A large MSCA Innovative Training Network running 2018–2022, where BRI.TECH's implant technology was studied using cutting-edge imaging and biochemical assays, placing them at the centre of European-level safety research on biodegradable magnesium devices.